Gastric Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Conditions
Keywords
Gastric or Gastroesophageal Junction Adenocarcinoma
Brief summary
The primary purpose of the study is to determine the impact of chemotherapy on the ability of your surgeon to completely remove the cancer as well as the impact on your survival. Furthermore the investigators will be assessing the side effects of this chemotherapy strategy. Finally the investigators will determine the ability of specialized imaging technology (PET scan) to document and predict the response of the tumor to this chemotherapy. Standard therapy for patients with your condition usually consists of surgery (removal of the tumor) followed by combination chemotherapy and radiotherapy. More recently, standard options available to patients with cancer of the stomach or lower esophagus have been expanded to include chemotherapy without radiotherapy prior to and following surgery. While it is believed that chemotherapy prior to surgery is a good option for patients with stomach, it is not known what is the optimal chemotherapy regimen to offer patients prior to surgery to improve the likelihood of cure while limiting side-effects to patients.
Interventions
DRUGTaxotere, Cisplatin, and 5-FU
Taxotere/Cisplatin/5-FU x 3 cycles (3 weeks per cycle or 9 weeks total), 1 - 2 weeks, Taxotere/Cisplatin/5-FU x 3 cycles (3 weeks per cycle or 9 weeks total)
Sponsors
McGill University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Histological diagnosis of adenocarcinoma of the stomach, gastroesophageal junction (GEJ), or lower third of the esophagus. * The tumour must be deemed by the team to be potentially resectable. This includes imaging studies (detailed below) to clinically stage the tumour and rule-out the presence of metastatic disease, and includes a preoperative laparoscopic evaluation. * Stage IB (T1N1 only), II, IIIA, IIIB, and IV (T4N1 only) * Life expectancy greater than 3 months * ECOG performance status of 1 or better (i.e. restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work). * Adequate hematologic reserve: Platelet count 100,000/L, WBC 2000/μL * Creatinine clearance 60 ml/min, AST & ALT 2 ULN, Alkaline phosphatase 2.5 ULN, bilirubin ULN
Exclusion criteria
* Prior systemic therapy for gastric cancer * Prior docetaxel-containing chemotherapy * Pre-existing medical conditions precluding treatment, including any contraindication for major surgery * Pregnancy or lactating mothers. Women of childbearing age must use contraception during and for 3 months following treatment. * Unable to give informed consent * Patients that are not able to maintain nutrition by oral consumption of food alone must have additional enteral feeding. * Patients with macroscopic disease noted at laparoscopy * ECOG performance status of 2 or higher * Significant hearing impairment, as judged by the need for or use of a hearing aid. If there is any uncertainty regarding the degree of hearing impairment, an audiogram will be done. If the audiogram is grossly normal or shows only minor hearing impairment (i.e. not requiring hearing aid), the patient may be enrolled. * Unwillingness to undergo investigations and/or treatment as outlined on the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the impact of chemotherapy on the ability of your surgeon to completely remove the cancer as well as the impact on your survival. | — |
Countries
Canada
Contacts
Primary ContactLorenzo Ferri
Backup ContactSteven Ades
Outcome results
None listed